Abcam PLC - Cambridge, England-based life science research tools - After changing year-end accounting date, publishes interim and annual results ended June 30. Swings to pretax profit in six months to June 30 of GBP9.2 million from GBP17.6 million loss year before. Interim revenue rises to GBP150.2 million from GBP121.8 million. In the 12 month period, pretax profit grows to GBP25.4 million from GBP8.4 million, as revenue rises to GBP297.7 million from GBP260.0 million.
Chief Executive Alan Hirzel says: "Our team is dedicated to supporting life science discovery and the translation of discovery to social impact. Our financial performance, including 29% revenue growth, is one indicator of the trust the market has in our team, our innovation, and our brand.
"As I look ahead, I am convinced more than ever that we can extend our market leadership, sustain durable growth, and become an increasingly influential partner within our industry."
Notes laboratory activity and demand have continued to gradually recover and trading performance year-to-date is in line with the company's expectations, with mid-teens constant exchange rate revenue growth in July and August.
Current stock price: 1,494.00 pence, down 1.6% Monday
Year-to-date change: down 3.6%
By Paul McGowan; paulmcgowan@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.